PRODISC L
Centinel Spine, LLC · Decision date Sep 2, 2025
What did the FDA approve?
FDA records P050010/S027 as a supplement to PMA P050010, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Sep 2, 2025.
FDA approval order statement
approval of an alternate manufacturing site, Summit Orthopedic Technologies Inc. (FEI 3012491394) for machining, cleaning, and passivation of the Prodisc L implants
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Orthopedic
- Decision date
- Sep 2, 2025
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P050010/S027
- Regulatory pathway
- PMA supplement
- Applicant
- Centinel Spine, LLC
- Product code
- MJO
- Decision code
- APPR
- Decision date
- Sep 2, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, intervertebral disc.
- Applicant
- Centinel Spine, LLC
- Product code
- MJO
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P050010/S027 received
Application receipt date recorded by FDA.
P050010/S028 · Related supplement
prodisc L
P050010/S027 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P050010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
prodisc LP050010/S028 | Centinel Spine, LLC | PMA supplement | Jul 30, 2025 | FDA |
Explore the linked device profile
Other records with product code MJO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BAGUERAC Cervical Disc ProsthesisP250042/S002 | Spineart USA, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Synergy DiscP250028/S003 | Synergy Spine Solutions, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
prodisc C NovaP070001/S031 | Centinel Spine, LLC | PMA supplement | Sep 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Centinel Spine, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 900 Airport Rd., Suite 3b, West Chester, PA, 19380
Sources and methodology
- Original FDA record: P050010/S027
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


